Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

This systematic review and meta-analysis evaluates the efficacy and safety of retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, for the treatment of obesity. Evidence from randomized controlled trials indicates significant weight reduction and metabolic improvements, with an acceptable safety and tolerability profile.